Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
LEHI, Utah, Oct. 23, 2025 — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on therapies targeting the root...
TAIPEI, Taiwan – October 23, 2025 AnnJi Pharmaceutical Co., Ltd. (AJ Pharm) announced that the U.S. Food and Drug...
SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...
Basel, Switzerland – October 23, 2025: Swiss Rockets AG has announced a strategic partnership with Squirro AG aimed at...
Foster City, California – October 20, 2025 — Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will present new...
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
Toronto, Canada – October 22, 2025 — Visionary Holdings Inc., a global education and technology enterprise, announced the launch...
Nanjing, China – October 22, 2025 GemPharmatech Co., Ltd., a global leader in genetically engineered mouse models and preclinical...
NEW YORK, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by...
